Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.10 and traded as high as $8.24. Regulus Therapeutics shares last traded at $8.20, with a volume of 1,160,072 shares traded.
Analyst Upgrades and Downgrades
Several research analysts have commented on RGLS shares. Leerink Partners reiterated a "market perform" rating and issued a $7.00 target price on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Canaccord Genuity Group reiterated a "hold" rating and issued a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Leerink Partnrs cut shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Wall Street Zen started coverage on shares of Regulus Therapeutics in a report on Sunday, May 18th. They issued a "sell" rating for the company. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $9.00 target price on shares of Regulus Therapeutics in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $8.50.
View Our Latest Research Report on Regulus Therapeutics
Regulus Therapeutics Trading Down 0.2%
The company has a market cap of $567.69 million, a PE ratio of -11.23 and a beta of 0.35. The business's 50-day simple moving average is $6.27 and its 200-day simple moving average is $3.10.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. On average, research analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.
Insider Activity at Regulus Therapeutics
In other Regulus Therapeutics news, insider Preston Klassen acquired 12,000 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were purchased at an average price of $7.99 per share, with a total value of $95,880.00. Following the completion of the transaction, the insider now owns 48,055 shares in the company, valued at $383,959.45. The trade was a 33.28% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.35% of the company's stock.
Hedge Funds Weigh In On Regulus Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Regulus Therapeutics by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,345 shares of the biopharmaceutical company's stock valued at $67,000 after acquiring an additional 1,644 shares in the last quarter. PEAK6 LLC bought a new position in shares of Regulus Therapeutics in the fourth quarter valued at approximately $95,000. Oppenheimer & Co. Inc. bought a new position in shares of Regulus Therapeutics in the first quarter valued at approximately $96,000. Velan Capital Investment Management LP bought a new position in shares of Regulus Therapeutics in the fourth quarter valued at approximately $111,000. Finally, AQR Capital Management LLC bought a new position in shares of Regulus Therapeutics in the first quarter valued at approximately $120,000. Institutional investors own 92.38% of the company's stock.
Regulus Therapeutics Company Profile
(
Get Free Report)
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
